Spondyloarthritis

Interchangeability Observed Between 2 Measures of Minimal Disease Activity in Psoriatic Arthritis

Researchers assessed the interchangeability of 2 measures of minimal disease activity in psoriatic arthritis.

Greater Joint and Skin Improvement With Ixekizumab vs Adalimumab in Patients With Psoriatic Arthritis

Researchers determined the efficacy and safety of ixekizumab vs adalimumab in bionaive patients with psoriatic arthritis.

Diabetes, CVD, and PsA May Be Prevalent in Patients With Palmoplantar Plaque Psoriasis

The relationship of palmoplantar plaque psoriasis and comorbidities known to be associated with generalized plaque psoriasis were examined.

Top US Experts in Psoriatic Arthritis Identified

Expertscape has developed an online physician ranking search tool to help identify the providers and researchers with leading expertise in psoriatic arthritis and other specialties.

Sleep Disturbances, Fatigue, and Depression Common Among Patients With Psoriatic Arthritis

Researchers explored the occurrence of sleep disturbances, fatigue, and anxiety/depression in patients with psoriatic arthritis.

Vitamin D Deficiency Associated With Increased Inflammatory Activity in Spondyloarthritis

Researchers evaluated the association between vitamin D deficiency and inflammatory activity in patients with spondyloarthritis.

Evaluating Outcomes of Switching Between TNF Inhibitors in Patients With Axial Spondyloarthritis

Researchers assessed whether the reason to discontinue the first TNF inhibitor (TNFi) affected the response to the second TNFi in axial spondyloarthritis.

Anti-CD74 Antibodies Identified as Promising Tool to Support Diagnosis of Axial Spondyloarthritis

Researchers evaluated the role of anti-CD74 antibodies in the diagnosis of axial spondyloarthritis and their association with disease duration and activity.

Methotrexate Superior to Sulfasalazine as First-Line csDMARD Monotherapy in Patients With PsA

Researchers evaluated drug retention and predictors for drug retention among patients with psoriatic arthritis receiving first-line conventional synthetic DMARD monotherapy.

Upadacitinib Application for Ankylosing Spondylitis Submitted for Review

The application is supported by data from the multicenter, double-blind, placebo-controlled phase 2/3 SELECT-AXIS 1 study.